Multicenter Study of Outcomes with Ceftazidime-Avibactam in Patients with Carbapenem-Resistant Enterobacteriaceae Infections | Zendy

Madeline King | Zendy; Emily L. Heil | Zendy; Safia Kuriakose | Zendy; Tiffany E. Bias | Zendy; Vanthida Huang | Zendy; Claudine ElBeyrouty | Zendy; Dorothy McCoy | Zendy; Jon Hiles | Zendy; Lynette Richards | Zendy; Julianne Gardner | Zendy; Nicole Harrington | Zendy; Kenneth Biason | Zendy; Jason C Gallagher | Zendy

Open Access

Multicenter Study of Outcomes with Ceftazidime-Avibactam in Patients with Carbapenem-Resistant Enterobacteriaceae Infections

Author(s) -

Madeline King,

Emily L. Heil,

Safia Kuriakose,

Tiffany E. Bias,

Vanthida Huang,

Claudine ElBeyrouty,

Dorothy McCoy,

Jon Hiles,

Lynette Richards,

Julianne Gardner,

Nicole Harrington,

Kenneth Biason,

Jason C Gallagher

Publication year - 2017

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00449-17

Subject(s) - ceftazidime/avibactam , avibactam , ceftazidime , medicine , cephalosporin , carbapenem resistant enterobacteriaceae , enterobacteriaceae , carbapenem , beta lactamase inhibitors , intensive care medicine , population , microbiology and biotechnology , antibiotics , biology , escherichia coli , pseudomonas aeruginosa , bacteria , biochemistry , genetics , environmental health , gene

Ceftazidime-avibactam is a novel cephalosporin–beta-lactamase inhibitor combination that is active against many carbapenem-resistantEnterobacteriaceae (CRE). We describe a retrospective chart review for 60 patients who received ceftazidime-avibactam for a CRE infection. In-hospital mortality was 32%, 53% of patients had microbiological cure, and 65% had clinical success. In this severely ill population with CRE infections, ceftazidime-avibactam was an appropriate option.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research